Frequently asked questions in drug combinations and the mass-action law-based answers

Synergy

Volumn 1, Issue 1, 2014, Pages 3-21

  Chou, Ting Chao ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Combination index; Computer synergy simulation; Dose reduction index; Isobologram; Median effect equation; Polygonogram

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CISPLATIN; PACLITAXEL; TOPOTECAN;

ALGORITHM; CLINICAL TRIAL (TOPIC); COMPUTER PROGRAM; COMPUTER SIMULATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG USE; HUMAN; IC50; MASS ACTION; MATHEMATICAL MODEL; PRIORITY JOURNAL; REVIEW; STUDY DESIGN;

EID: 84921827228     PISSN: 22137130     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.synres.2014.07.003     Document Type: Review

References (99)

1. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58:621-681. http://pharmrev.aspetjournals.org/cgi/reprint/58/3/621.
2. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
3. Greco W.R., Bravo G., Parsons J.C. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995, 47:331-385.
4. Chou T.C. What is synergy?. Scientist 2007, 21:15.
5. Chou T.C. Preclinical versus clinical drug combination studies. Leuk Lymphoma 2008, 49:2059-2080.
6. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010, 70:440-446.
7. Chou T.C. The mass-action law based algorithms for quantitative econo-green bio-research. Integr Biol 2011, 3:548-559.
8. Chou T.C. The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development. Am J Cancer Res 2011, 1:925-954.
9. Fraser T.R. The antagonism between the actions of active substances. Brit Med J 1872, 2:485-487.
10. Loewe S. Antagonism and antagonist. Pharmacol Rev 1957, 9:237-242.
11. Finney D.J. Probit analysis 1952, 146-153. Cambridge University Press, London/New York. 2nd ed.
12. Goldin A., Mantel N. The employment of combinations of drugs in the chemotherapy of neoplasia: a review. Cancer Res 1957, 17:635-654.
13. Ashford J.R. General models for the joint action of mixtures of drugs. Biometrics 1981, 37:457-474.
14. Berenbaum M.C. What is synergy?. Pharmacol Rev 1989, 41:93-141.
15. Poch G., Reiffenstein R.J., Unkelbach H.D. Application of the isobologram technique for the analysis of combined effects with respect to additivity as well as independence. Can J Physiol Pharmacol 1990, 68:682-688.
16. Prichard M.N., Shipman C. A three-dimensional model to analyze drug-drug interactions. Antiviral Res 1990, 14:181-205.
17. Tallarida R.J. Statistical analysis of drug combinations for synergism. Pain 1992, 49:93-97.
18. Chou T.C. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 1976, 59:253-276.
19. Chou T.C., Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 1983, 4:450-454.
20. Chou T.C. The median-effect principle and the combination index for quantitation of synergism and antagonism. Synergism and antagonism in chemotherapy 1991, 61-102. Academic Press, San Diego. T.C. Chou, D.C. Rideout (Eds.).
21. Chou T.C. The mass-action law based GPS concept for bio-informatics. Nat Preced 2008, (npre.2008.2064-2). Available at: http://precedings.nature.com/documents/2064/version/2 [accessed on 22.07.08].
22. Chou T.C. Combinatorial analysis of multiple substrate-multiple product enzyme reactions. J Theor Biol 1972, 35:285-297.
23. Chou T.C. Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition. Mol Pharmacol 1974, 10:235-247.
24. Chou T.C. On the determination of availability of ligand binding sites in steady-state systems. J Theor Biol 1977, 65:345-356.
25. Chou T.C. Quantitative dose-effect analysis and algorithms: a theoretical study. Asia Pac J Pharmacol 1987, 2:93-99.
26. Chou T.C., Chou J.H. Distinction between multiple ligand exclusivity and competitiveness in receptor binding topology. FASEB J 1988, 2:A1778.
27. Chou J.H., Chou T.C. Computerized simulation of dose reduction index (DRI) in synergistic drug combinations. Pharmacologist 1988, 30:A231.
28. Chou T.C., Chou J.H. The median-effect equation: a unified form for Michaelis-Menten, Hill, Scatchard and Henderson-Hasselbalch equations. FASEB J 1990, 6:A824.
29. Chou T.C., Talalay P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 1977, 252:6438-6442.
30. Chou T.C. l-Asparagine biosynthesis and its control 1970, [Ph.D. thesis], Yale University, New Haven, CT.
31. Chou T.C., Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 1981, 115:207-216.
32. Chou T.C., Talalay P. Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents. New avenues in developmental cancer chemotherapy 1987, 37-64. Academic Press, New York. K.R. Harrap, T.A. Connors (Eds.).
33. 50, synergism, antagonism, low-dose risk, receptor ligand binding and enzyme kinetics. Computer software for Apple II series 1985, Elsevier-Biosoft, UK.
34. Chou T.C., Hayball M.P. CalcuSyn for Windows. Multiple-drug dose-effect analyzer and manual 1997, Biosoft, Cambridge, UK.
35. Chou T.C., Martin N. CompuSyn for Drug Combinations: PC Software and User's Guide. A computer program for quantitation of synergism and antagonism in drug combinations, and the determination of IC50 and ED50 and LD50 values 2005, ComboSyn, Paramus, NJ, [Free download beginning 08.01.12]. mailto:combosyn@gmail.com.
36. Chou T.C., Chou J.H. Computerized indexing of drug combinations: prediction of synergism and antagonism of more than two drugs by polygonogram. FASEB J 1998, 12:832.
37. Chou T.C., Motzer R.J., Tong Y., Bosl G.J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994, 86:1517-1524.
38. + cells per cubic millimeter. N Engl J Med 1995, 333:1662-1669.
39. Mildvan D., Bassiakos Y., Zucker M.L., Hyslop N., Krown S.E., Sacks H.S., et al. Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clinical Trial Group 068. Antivir Ther 1996, 1:77-88.
40. Chou J.H. Quantitation of synergism and antagonism of two or more drugs by computerized analysis. Synergism and antagonism in chemotherapy 1991, 223-244. Academic Press, New York. T.C. Chou, D.C. Rideout (Eds.).
41. Chou T.C. On the revelation of the Confucian doctrine of the mean in modern science principle. Proc Am Philo Assoc East Annual Meeting 2007, 47.
42. Chou T.C. A new look at the ancient Asian philosophy through modern mathematical and topological scientific analysis (as a symposium speaker in Section 2). The World Congress of Philosophy 2008.
43. Chou T.C. On the complement between ancient Chinese philosophy and modern science algorithms. 16th international conference of Chinese philosophy/Chinese association of philosophy 2009, Published in electronic memory drive, No. D-16.
44. Conti J.A., Otter G., Sirotnak F.M. Irinotecan (CPT-11) is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996, 14:709-715.
45. 3N, and their use in combination with doxorubicin or paclitaxel. Cancer Chemother Pharmacol 2006, 58:640-653.
46. Koechli O.R., Sevin B.U., Peras J.P., Chou T.C., Angioli R., Steren A., et al. Characteristics of the combination taxol-adriamycin in breast cancer cell lines analyzed with the ATP-cell-viability-assay. Breast Cancer Res Treat 1993, 28:21-27.
47. Singh B., Reddy P.G., Goberdhan A., Walsh C., Dao S., Chou T.C., et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Gene Dev 2002, 16:984-993.
48. Fitzgerald J.B., Schoeberl B., Nielsen U.B., Sorger P.K. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2006, 2:458-466.
49. Aghi M., Kramm C.M., Chou T.C., Breakefield X.O., Chiocca A. Synergistic anticancer effects of the ganciclovir/thymidine kinase and 5-fluorocytosine/cytidine deaminase gene therapies. J Natl Cancer Inst 1998, 90:370-380.
50. Aghi M., Chou T.C., Suling K., Breakefield X.O., Chiocca E.A. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 1999, 59:3861-3865.
51. Lehar J., Stockwell B.R., Giaever G., Nislow C. Combination chemical genetics. Nat Chem Biol 2008, 4:674-681.
52. Astsaturov I., et al. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal 2010, 3:ra67.
53. Zhang J.M., et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 2010, 463. 501-U116.
54. Adrian F.J., et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2006, 2:95-102.
55. Wallin J.J., et al. Nuclear phospho-Akt increase predicts synergy of P13K inhibition and doxorubicin in breast and ovarian cancer. Sci Transl Med 2010, 2:48ra66.
56. Tse A.N., Sheikh T.N., Alan H., Chou T.C., Schwartz G.K. 90-kDa heat shock protein inhibition aboragates the topisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1. Mol Pharmacol 2009, 75:124-133.
57. Chang B.K., Gutman R., Chou T.C. Schedule-dependent interaction of α-difluoromethylornithine and cis-diammine-dichloroplatinum (II) against pancreatic cancer cell lines. Cancer Res 1987, 47:2247-2250.
58. Perez E.A., Hack F.M., Webber L.M., Chou T.C. Schedule dependence of synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by the median-effect analysis. Cancer Chemother Pharmacol 1993, 33:245-250.
59. Takahashi N., et al. Sequence dependent synergistic cytotoxicity of Ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res 2002, 62:6909-6915.
60. Adusumilli P.S., Chan M.K., Chun Y.S., Hezel M., Chou T.C., Rush V.W., et al. Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biol Therapy 2006, 5:48-53.
61. 1 34.5 deleted oncolytic herpes virus (G207). FASEB J 2004, 18:1001-1021.
62. Dai M.H., Zamarin D., Gao S.P., Chou T.C., Gonzalez L., Lin S.F., et al. The synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. Brit J Surg 2010, 97:1385-1394.
63. Adusumilli P.S., Stilis B.M., Chan M.K., Chou T.C., Wong R.J., Rusch V.W., et al. Radiation therapy potentiates effective oncolytic viral therapy efficacy in the treatment of lung cancer. Ann Thoracic Surg 2005, 80:409-417.
64. Ito E., et al. Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer. Sci Transl Med 2011, 3:67ra7.
65. Seiwert T.Y., Salama J.K., Vokes E.E. The concurrent chemoradiation paradigm-general principles. Nat Clin Prac Oncol 2007, 4:86-100.
66. Nyati M.K., Morgan M.A., Feng F.Y., Lawrence T.S. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006, 6:876-885.
67. Keith C.T., Borisy A.A., Stockwell B.R. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005, 4. 71-U10.
68. Yang W., Huo T., Barth R.F., Gupta N., Weldon M., Grecula J.C., et al. Convection enhanced delivery of carboplatin in combination with radiotherapy for the treatment of brain tumor. J Neurooncol 2010, 101:379-390.
69. Chang T.T., Gulati S.C., Chou T.C., Vega R., Gandola L., Ibrahim S., et al. Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on HL-60 myelogenous leukemia cell line demonstrated by computer analysis. Cancer Res 1985, 45:2434-3439.
70. Chang T.T., Gulati S.C., Chou T.C., Colvin M., Clarkson B. Comparative cytotoxicity of various drug combinations for human leukemic cells and normal hematopoietic precursors. Cancer Res 1987, 47:119-122.
71. Khafif A., Schantz S.P., Chou T.C., Edelstein D., Sacks P.G. Quantitation of chemopreventive synergism between (-) - epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Carcinogenesis 1998, 19:419-424.
72. Soriano A.F., Helfrich B., Chan D.C., Heasley L.E., Bunn P.A., Chou T.C. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell line. Cancer Res 1999, 59:6178-6184.
73. Hartshorn K.L., Vogt M.W., Chou T.C., Blumberg R.S., Byington R., Schooley R.T., et al. Synergistic inhibition of human immunodeficiency virus in vitro by azidotymidine and recombinant interferon alpha-A. Antimicrob Agents Chemother 1987, 31:168-172.
74. Vogt M.W., Hartshorn K.L., Furman P.A., Chou T.C., Fyte J.A., Coleman L.A., et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987, 235:1376-1379.
75. Richman D., Rosenthal A.S., Skoog M., Eckner R.J., Chou T.C., Sabo J.P., et al. BI-RG-587 is active against AZT-resistant HIV-1 and synergies with AZT. Antimicrob Agents Chemother 1991, 35:305-308.
76. Ruprecht R.M., Chou T.C., Chipty F., Gamasusa M., Mullaney S., O'Brien L., et al. Interferon α and 3'-azido-3'-deoxythymidine are highly synergistic in vivo and prevent viremia after acute retrovirus exposure. J AIDS 1990, 3:591-600.
77. Tremblay C.L., Kollmann C., Giguel F., Chou T.C., Hirsch M.S. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J AIDS 2000, 25:99-102.
78. Johnson V.A., Merrill D.P., Videler J.A., Chou T.C., Byington R.E., Eron J.J., et al. Two-drug combinations of zidovudine, didanosine and recombinant interferon-alpha A inhibit replication of zidovudine-resistant HIV-1 synergistically in vitro. J Infect Dis 1991, 164:646-655.
79. Shen L., et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008, 14:762-766.
80. Johnson V.A., Merrill D.P., Chou T.C., Hirsch M.S. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor RO131-8959 and Zidovudine, 2',3'-dideoxycytidine or recombinant interferon-alpha-A against using AZT-sensitive or resistant HIV-1 in vitro. J Infect Dis 1992, 166:1143-1146.
81. Kong X.B., Zhu Q.Y., Stein C.A. Synergistic inhibition of HIV-1 replication in vitro by two drug and three drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate and 2', 3'-dideoxythymidine. Antimicrob Agents Chemother 1991, 35:2003-2011.
82. Johnson V.A., Barlow M.A., Merrill D.P., Chou T.C., Hirsch M.S. Three drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4 and interferon alpha-A. J Infect Dis 1990, 161:1059-1067.
83. Pan X.Z., Qui Z.D., Baron P.A., Gold J.W.M., Polsky B., Chou T.C., et al. Three-drug synergistic inhibition of HIV-1 replication in vitro by 3'-fluoro-3'-deoxythymidine, recombinant soluble CD4, and recombinant interferon-alpha A. AIDS Res Human Retrovir 1992, 8:589-595.
84. Zhu Q.Y., Scarborough A., Polsky B., Chou T.C. Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV-type 1 strains. AIDS Res Human Retrovir 1996, 12:507-517.
85. Baba T.W., Liska V., Hofman-Lehmann R., Vlasak J., Xu W., Ayehunie S., et al. Human neutralizing monoclonal antibodies of the IgG1 subtype completely protect against mucosal simian-human HIV infection. Nat Med 2000, 6:200-206.
86. Tilley S.A., Honnen W.J., Racho M.E., Chou T.C., Pinter A. Synergistic naturalization of HIV-1 by HuMAbs against the V3 loop and the CD4 binding site of gp120. AIDS Res Hum Retrovir 1992, 8:461-467.
87. Li A., Baba T.W., Sodroski J., Zolla-Panzner S., Gorny M.K., Robinson J., et al. Synergistic neutralization of a chimeric SIV/HIV-1 virus with combinations of human anti-HIV-1 envelope monoclonal antibodies or hyper immune globulins. AIDS Res Hum Retrovir 1997, 13:647-656.
88. Ruprecht R.M., Ferrantelli F., Rasmussen R.A., Xu W., Kitabwalla M., Fofmann-Lehmann R., et al. Neutralizing antibodies: a potent line of defense against acute and chronic simian-human immunodeficiency virus infection. Retroviruses of human AIDS and related animal diseases 2002, 45-50. M. Vicari, B. Ordet, M. Girad (Eds.).
89. Hofmann-Lehmann R., Vlasak J., Rasmussen R.A., Smith B.A., Baba T.W., Liska V., et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol 2001, 75:7470-7480.
90. Kahan B.D., Gibbons S., Tejpal N., Stepkowski S.M., Chou T.C. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991, 51:232-239.
91. Vathsala A., Goto S., Yoshimura N., Stepkowski S., Chou T.C., Kahan B.D. Immunosuppressive antagonism of low doses of FK506 and cyclosporine. Transplantation 1991, 52:121-128.
92. Stepkowski S.M., Tu Y., Chou T.C., Kahan B.D. Synergistic interactions of cyclosporine, rapamycin, and brequinar on heart allograft survival in mice. Transplant Proc 1994, 26:3025-3027.
93. Stepkowski S.M., Tian L., Napoli K.L., Ghobrial R., Wang M.E., Chou T.C., et al. Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection. Clin Exp Immunol 1997, 108:63-68.
94. Kahan B.D., Gibbons-Stubbers S., Tejpal N., Chou T.C. Prospects for synergistic immunosuppressive drug therapy in the coming decade. Transplant Proc 1992, 24:1263-1265.
95. Chou T.C., Kahan B.D. A rigorous approach to the diagnosis of immunosuppressive synergy combination therapy. Modern immunosuppressives: milestones in drug therapy 2001, 183-200. Birkhauser, Switzerland. H.J. Schuurman (Ed.).
96. Chou T.C., Dong H.J., Timmermans P.B.M.W.M. Design, experimentation and computerized automated data analysis of synergistic drug combinations against xenograft tumors by Taxotere and T-900607. Proc Amer Assoc Cancer Res 2005, 46:1167.
97. Chou T.C. Drug combination against xenograft tumors in nude mice: experimental design, execution, and computerized simulation of synergism and antagonism (an abstract for the mini-symposium). Proc Am Assoc Cancer Res 2008, 49:997.
98. Webb J.L. Effect of more than one inhibitor. Enzyme and metabolic inhibitors 1963, vol. 1:66-79. Academic Press, New York, 488-512.
99. Lineweaver H., Burk D. The determination of enzyme dissociation constants. J Am Chem Soc 1934, 56:658-666.